SciSparc announces Clearmind filed three patents

SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), Clearmind filed three patent applications under the international Patent Cooperation Treaty. The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine and Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide. “We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset,” said SciSparc’s Chief Executive Officer, Oz Adler. “We believe in the added value that CannAmide can offer when combined with various psychedelic compounds that are known for their therapeutics advantages.”